Jozef Pacák
Valvular aortic stenosis (AoS) is the most common valvular disease. In our institute patients with pure AoS represented 56 % of all patients with valvular disease. Pharmacological therapy is not solution and is reserved only for those patients who could not be indicated for surgical or transcatheter treatment. The gold standard of the treatmen of symptomatic AoS is a surgical replacement of the stenotic aortic valve. Acute and the long term results are very good, even in the group of very ill patients with low LVEF (left ventricular ejection fraction) and over 71. Transcatheter balloon aortic valvuloplasty does not reach good results and is reserved only as a bridging for surgical replacement of the valve. Currently a new transcateter therapy- implantation of percutaneous heart valve (PHV) has been developing. There are two ways of implantation: an antegrade from the femoral vein and with the need of transeptal approach and a retrograde, which is considered technically less demand. The results are very promising, but technique and devices are still in development. The use of transcatheter implantation of PHV in aortic position will likely expand particularly for very risk patient for surgical treatment.